Condition
X-Linked Adrenoleukodystrophy (X-ALD)
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Allohsct
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
Trial Status
Active Not Recruiting1
Terminated1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02698579Active Not Recruiting
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
NCT02204904TerminatedPrimary
Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)
Showing all 2 trials
Research Network
Common Treatments
- Allohsct1
- Elivaldogene Autotemcel1
- No Interventional Drug Product Utilized In This Followup Study1
Active Sponsors
- Genetix Biotherapeutics Inc.2
Top Investigators
bluebird bio, Inc.
Genetix Biotherapeutics Inc.
Related Conditions
- Adrenoleukodystrophy Ald2
- Cerebral Adrenoleukodystrophy Cald2